Public-private partnerships can help engage industry in AIDS vaccine research. Pharma and biotechnology companies should respond with the expertise that only they can offer.
Jun 1, 2005
When G8 leaders meet in early July in Scotland, international health and development will be high on the agenda, and AIDS vaccines likely will be recognized once again as a global priority. Growing political support for AIDS vaccine research is vitally important, but we also know its ultimate impact will be limited unless the pharmaceutical and biotechnology industries become more energetically engaged.